BRPI0918288A2 - derivados de pirrolidino- ciclopropano fundidos como inibidores seletivos de 11-beta-hidroxiesteroide disidrogenase do tipo 1 - Google Patents

derivados de pirrolidino- ciclopropano fundidos como inibidores seletivos de 11-beta-hidroxiesteroide disidrogenase do tipo 1

Info

Publication number
BRPI0918288A2
BRPI0918288A2 BRPI0918288A BRPI0918288A BRPI0918288A2 BR PI0918288 A2 BRPI0918288 A2 BR PI0918288A2 BR PI0918288 A BRPI0918288 A BR PI0918288A BR PI0918288 A BRPI0918288 A BR PI0918288A BR PI0918288 A2 BRPI0918288 A2 BR PI0918288A2
Authority
BR
Brazil
Prior art keywords
dehydrogenase
beta
selective inhibitors
cyclopropane derivatives
fused pyrrolidine
Prior art date
Application number
BRPI0918288A
Other languages
English (en)
Inventor
Denis Carniato
Didier Roche
Eric Valeur
Fabien Schmidlin
Franck Lepifre
Serge Christmann-Franck
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0918288A2 publication Critical patent/BRPI0918288A2/pt
Publication of BRPI0918288B1 publication Critical patent/BRPI0918288B1/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Child & Adolescent Psychology (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
BRPI0918288-8A 2008-09-01 2009-08-05 derivados de pirrolidino-ciclopropano fundidos, medicamento, composição farmacêutica, e kit BRPI0918288B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08290822 2008-09-01
EP08290822.9 2008-09-01
PCT/EP2009/005654 WO2010022850A1 (en) 2008-09-01 2009-08-05 Fused pyrrolidino-cyclopropane derivatives as selective 11-beta-hydroxysteroid dehydrogenase type 1 inhibitors

Publications (2)

Publication Number Publication Date
BRPI0918288A2 true BRPI0918288A2 (pt) 2015-12-22
BRPI0918288B1 BRPI0918288B1 (pt) 2018-11-06

Family

ID=41095854

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0918288-8A BRPI0918288B1 (pt) 2008-09-01 2009-08-05 derivados de pirrolidino-ciclopropano fundidos, medicamento, composição farmacêutica, e kit

Country Status (15)

Country Link
US (1) US8486964B2 (pt)
EP (1) EP2321317B1 (pt)
JP (1) JP5579717B2 (pt)
KR (1) KR101707580B1 (pt)
CN (1) CN102137864B (pt)
AR (1) AR073224A1 (pt)
AU (1) AU2009287118B9 (pt)
BR (1) BRPI0918288B1 (pt)
CA (1) CA2735286C (pt)
EA (1) EA020238B1 (pt)
ES (1) ES2531633T3 (pt)
IL (1) IL211447A (pt)
MX (1) MX2011002181A (pt)
WO (1) WO2010022850A1 (pt)
ZA (1) ZA201102418B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015061272A1 (en) * 2013-10-22 2015-04-30 Bristol-Myers Squibb Company Isotopically labeled triazolopyridine 11-beta hydroxysteroid dehydrogenase type i inhibitors
MA40759A (fr) 2014-09-26 2017-08-01 Pfizer Modulateurs de rorc2 de type pyrrolopyridine substitué par un méthyle et trifluorométhyle et leurs procédés d'utilisation
EP3235813A1 (en) 2016-04-19 2017-10-25 Cidqo 2012, S.L. Aza-tetra-cyclo derivatives
KR20240125035A (ko) * 2021-12-21 2024-08-19 코어셉트 쎄라퓨틱스 인코포레이티드 이환 인다졸 글루코코르티코이드 수용체 길항제

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088652A (en) * 1975-07-31 1978-05-09 American Cyanamid Company Acylazabicyclohexanes
US20060195164A1 (en) * 2003-01-08 2006-08-31 Sondergaard Jorgen C Electro-therapeutic device and method of electro-therapeutic treatment
DE602004027171D1 (de) * 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
WO2006106423A2 (en) * 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
WO2007054577A1 (en) * 2005-11-14 2007-05-18 Probiodrug Ag Cyclopropyl-fused pyrrolidine derivatives as dipeptidyl peptidase iv inhibitors
GB0625198D0 (en) 2006-12-18 2007-01-24 Glaxo Group Ltd Chemical compounds

Also Published As

Publication number Publication date
ZA201102418B (en) 2011-12-28
EA201100419A1 (ru) 2011-10-31
CA2735286C (en) 2017-12-05
US20110172265A1 (en) 2011-07-14
KR20110059749A (ko) 2011-06-03
IL211447A (en) 2014-07-31
EP2321317A1 (en) 2011-05-18
EP2321317B1 (en) 2014-12-24
KR101707580B1 (ko) 2017-02-16
AU2009287118B2 (en) 2014-02-27
AU2009287118A1 (en) 2010-03-04
AU2009287118B9 (en) 2014-08-07
ES2531633T3 (es) 2015-03-18
MX2011002181A (es) 2011-03-30
CN102137864B (zh) 2014-12-31
CN102137864A (zh) 2011-07-27
EA020238B1 (ru) 2014-09-30
US8486964B2 (en) 2013-07-16
JP2012501302A (ja) 2012-01-19
BRPI0918288B1 (pt) 2018-11-06
IL211447A0 (en) 2011-05-31
WO2010022850A1 (en) 2010-03-04
JP5579717B2 (ja) 2014-08-27
AR073224A1 (es) 2010-10-20
CA2735286A1 (en) 2010-03-04

Similar Documents

Publication Publication Date Title
PT2860179T (pt) Derivados de pirazolo-piridina como inibidores de nadph-oxidase
BRPI0812825A2 (pt) Derivados ftalazinona como inibidores de parp-1
EP2320221A4 (en) ELECTRODE
DK2344682T3 (da) Elektrode for elektrolysecelle
BRPI0920135A2 (pt) imidazopiridazinacarbonitrilos úteis como inibidores de quinase
BRPI0911444A2 (pt) benzoimidazóis como inibidores de prolil hidroxilase
BRPI0913931A2 (pt) poliolefinas modificadas
BRPI0814441A2 (pt) Compostos de amida heterocíclica como inibidores de proteína cinase
EP2341824A4 (en) CONTOURED ELECTRODE
BR112012000792A2 (pt) compostos heterocíclicos como inibidores de autotaxina
BRPI1009800A2 (pt) compostos heterocíclicos como inibidores de autotaxina
BRPI0811065A2 (pt) Indazóis 5-heteroaril substituídos como inibidores de quinase
BRPI0911347A2 (pt) gama lactamas substituídas como agentes terapêuticos
BRPI0907641A2 (pt) Piridinas fundidas ativas como inibidores de c-met
BRPI0914724A2 (pt) eletrodo para solda
BRPI0818348A2 (pt) Derivados de n-(pirazol-3-il)-benzamida como ativadores de glicocinase
BRPI0920239A2 (pt) compostos heterocíclicos como inibidores de proteínas quinases
BRPI0910679A2 (pt) 5-metil-1-(naftaleno-2-il)-1h-pirazóis úteis como inibidores de receptor sigma
BRPI0912475A2 (pt) compostos como inibidores de quinase
IT1391986B1 (it) Ciabatta di tipo perfezionato
BRPI0914268A2 (pt) novo nrf2 oncogênico
BRPI0925050A2 (pt) Compostos heterocíclicos como inibidores de mek
BRPI0817061A2 (pt) Derivados de pirrolidinilalquilisoquinolinona e -isoindolinona como antagonistas de histamina-3
BRPI0914936A2 (pt) naftiridininonas como inibidores de aurora quinase
BRPI0816161A2 (pt) Transformante capaz de produzir isopropanol

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 05/08/2009, OBSERVADAS AS CONDICOES LEGAIS.

B21F Lapse acc. art. 78, item iv - on non-payment of the annual fees in time

Free format text: REFERENTE A 16A ANUIDADE.

B24J Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)

Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2846 DE 22-07-2025 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.